As early as February this year, China has reached vaccine export agreements with more than 20 countries, with a total order of more than 500 million doses, indicating that China has the strength of independent research and development and mass production, and the United States will give up the vaccine patent, which will not have much impact on the production, transportation and inoculation of vaccines in COVID-19.
We should be glad for it, for the timely screening and timely isolation in the early stage of the epidemic; Fortunately, we were born in China, and we were able to get vaccinated in time. We should also be happy to see the Chinese power behind it.
On the other hand, the vaccine situation in China:
After two doses of COVID-19 inactivated vaccine of China Bio-Beijing Company, Sinopharm Group, the vaccinators in the vaccine group all produced high titer antibodies, the positive conversion rate of neutralizing antibodies was 99.52%, and the protective effect of the vaccine on diseases caused by COVID-19 infection (coronavirus pneumonia-19) was 79.34%.
Under the national policy of free vaccination, the number of people vaccinated in COVID-19, China has exceeded 200 million. After excluding the number of people who are not suitable for vaccination due to health and age, nearly a quarter of people in China have been vaccinated with domestic vaccines. After such a large-scale vaccination, no serious adverse reactions have been found, so the safety factor is still very high.